TMS Icon
Scientific Literature

Fair Pricing of Innovative Medicines: An EHA Position Paper

Hagenbeek, A., Gribben, J., Jäger, U., et al. HemaSphere, 4(5), e488. (2020)

High prices keep innovative medicines out of reach for many patients across Europe, resulting in growing inequalities in accessibility and standards of care. Budgetary pressures compel payers and insurers to make increasingly difficult choices, at the expense of patients and investment in innovation.

Costly new therapies become available only for the lucky few —or for no one in those countries that lack the purchasing power or are left out of manufacturers’ marketing strategies altogether. With expensive combination therapies adding to the problem, the potential of scientific and medical innovation remains underused, not least in hematology.

By severely limiting the uptake of novel gene and cell therapies, high prices are undercutting efforts to increase, personalize and optimize treatment options for patients suffering from blood disorders.1

Read Publication
Back to top button